Metabolism - Clinical and Experimental
Volume 46, Issue 8 , Pages 918-925, August 1997

Antioxidant inhibition of protein kinase C—signaled increases in transforming growth factor-beta in mesangial cells

Department of Medicine, Veterans Affairs Medical Center, Pittsburgh and the University of Pittsburgh, Pittsburgh, PA USA

Received 24 September 1996; accepted 10 February 1997.

Abstract 

Protein kinase C (PKC)-signaled increases in transforming growth factor β (TGFβ) have been implicated in the stimulation of matrix protein synthesis induced by high concentrations of glucose, thromboxane, angiotension II (All), and other stimuli in cultured glomerular mesangial cells. In the present study, the effects of several antioxidants on mesangial cell responses to high glucose, thromboxane, and All were examined. α-Tocopherol blocked increases in PKC, TGFβ bioactivity, collagen, and/or fibronectin synthesis induced in mesangial cells by high glucose, the thromboxane analog U46619, and All. By contrast, α-tocopherol did not alter increases in matrix protein synthesis in mesangial cells in response to exogenous TGFIβ, a cytokine that does not activate PKC in mesangial cells and whose actions to stimulate matrix protein synthesis in these cells are not blocked by PKC inhibition or downregulation. Taurine and N-acetylcysteine similarly inhibited activation of PKC and increases in TGFβ in response to high glucose, U46619, and All, α-Tocopherol but not taurine or N-acetylcysteine partially blocked increases in PKC activity in mesangial cells in response to the diacylglycerol (DAG) analog, phorbol dibutyrate (PDBu). Thus, α-tocopherol may have direct effects on interaction of the PKC system of mesangial cells with DAG that are not shared by N-acetylcysteine or taurine. Increases in TGFβ have been implicated in the pathogenesis of glomerulosclerosis in diabetes and other nephropathies. The capacity of antioxidants to block increases in TGFβ in mesangial cells in response to high glucose, thromboxane, and All suggests their potential therapeutic utility to attenuate glomerulosclerosis.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the General Medical Research Service of the Department of Veterans Affairs and the American Diabetes Association.

PII: S0026-0495(97)90080-9

Metabolism - Clinical and Experimental
Volume 46, Issue 8 , Pages 918-925, August 1997